Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Comparative Genomic and Functional Characterization of Two Lytic Bacteriophages Against Antimicrobial-Resistant <i>Escherichia coli</i>.

Antibiotics (Basel, Switzerland)·2026
Same author

Immunocompromised Host Infectious Diseases: A Recommended Educational Content Outline for Advanced Practice Providers.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant.

American journal of hematology·2026
Same author

A decade of change: evolving epidemiology of invasive pulmonary mold infections in hematologic malignancy patients from a longitudinal infection control surveillance program.

Infection control and hospital epidemiology·2026
Same author

First report on remdesivir use for the treatment of respiratory syncytial virus in five allogeneic hematopoietic cell transplant recipients.

The Journal of infectious diseases·2026

Related Experiment Video

Updated: Jun 27, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Palivizumab: where to from here?

Georgiana Georgescu1, Roy F Chemaly

  • 1University of Texas MD Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, TX 77030, USA.

Expert Opinion on Biological Therapy
|December 10, 2008
PubMed
Summary

Palivizumab, an antibody for respiratory syncytial virus (RSV), significantly reduced hospitalizations in high-risk children. It shows promise for preventing and treating RSV in both immunocompetent and immunocompromised patients.

Area of Science:

  • Immunology
  • Virology
  • Pediatrics

Background:

  • Respiratory syncytial virus (RSV) causes significant illness, particularly in severely immunocompromised individuals.
  • Current treatments like aerosolized ribavirin have limitations, necessitating new strategies.
  • Palivizumab is an RSV-specific monoclonal antibody developed for prevention and treatment.

Purpose of the Study:

  • To review the role of palivizumab in preventing and treating RSV infections.
  • To evaluate palivizumab's effectiveness in immunocompetent and immunocompromised patients.
  • To discuss the safety and potential benefits of palivizumab.

Main Methods:

  • Review of a randomized, double-blind, placebo-controlled multicenter study.
  • Analysis of palivizumab's efficacy in high-risk children.

More Related Videos

Development of an IFN-&#947; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Experiment Videos

Last Updated: Jun 27, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Development of an IFN-&#947; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

  • Assessment of palivizumab's safety profile in immunocompromised patients.

    • Main Results:

    • Palivizumab significantly reduced hospitalization rates in high-risk children.
    • Palivizumab received FDA approval in June 1998 based on these findings.
    • Palivizumab demonstrates an excellent safety profile in immunocompromised patients.

    Conclusions:

    • Palivizumab is effective in preventing RSV hospitalizations in high-risk infants.
    • Palivizumab may offer benefits for RSV prevention and treatment in immunocompromised individuals.
    • Further clinical trials are needed to confirm palivizumab's effectiveness in immunocompromised populations.